13th May 2021 19:16
MaxCyte Inc - Maryland-based cell and gene therapies firm - Announces the consolidation of two of its lines of common stock into a single unrestricted line.
The consolidation will be effected by the transfer of all stock comprising the Regulation S restricted trading line, or MXCL to the unrestricted common stock trading line, also known as MXCT.
Following the consolidation, MaxCyte will have 84.4 million shares under the MXCT trading line issued overall.
Current stock price: 883.00 pence
Year-to-date change: up 67%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
MaxCyte